Mainz Biomed N.V. (operating as Quantum Cyber) Overview
Pro stress-test →Mainz Biomed N.V. is a molecular genetics cancer diagnostic company engaged in developing market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company is undergoing a major strategic transition, having announced a ticker change to QUCY effective March 12, 2026, with plans to officially change its corporate name to Quantum Cyber N.V. at a shareholder meeting scheduled for April 2026.
Strategic Profile
Pro stress-test →The corporate name change and stock ticker symbol change reflect the Company's business strategy and better reflect the future operations, which will include a shift toward quantum computing and cybersecurity-oriented offerings. However, the company faces significant financial headwinds: Mainz Biomed reported a net loss of $16.2 million for 2025 with revenue falling to $0.5 million, mainly from ColoAlert sales in Europe. The company is exiting its colorectal cancer business and focusing on a lower-cost pancreatic cancer screening program.
Competitive Landscape
Pro stress-test →The company historically offered ColoAlert, a colorectal cancer diagnostic molecular genetic stool test, and developed PancAlert, a stool-based screening test for pancreatic cancer detection. Traditional competitors in molecular cancer diagnostics include Exact Sciences (Cologuard for colorectal cancer) and Foundation Medicine, though the company's planned pivot to quantum computing and cybersecurity represents an entirely different competitive arena with limited clarity on market positioning.
Industry Context
Mainz Biomed N.V. (operating as Quantum Cyber) operates in Molecular cancer diagnostics (legacy business); quantum computing/cybersecurity (strategic pivot).
Key facts
Founded: 2008 · Headquarters: Mainz, Germany · Employees: N/A · Revenue: $0.5M (2025) · Market cap: $6.5M (as of April 2026)